Forget Johnson & Johnson: Another Healthcare Giant Is a Much Better Bet for Growth

Johnson & Johnson Overview - Johnson & Johnson is a top healthcare company focusing on innovative medicines and medical devices after spinning off its consumer health business [1] - The company expects a growth rate of 5-7% over the years but faces challenges such as talc lawsuits and the upcoming loss of exclusivity for its top-selling drug Stelara [1] Abbott Laboratories Overview - Abbott Laboratories has a more diverse business model compared to Johnson & Johnson, with revenue streams from nutrition, diagnostics, established pharmaceuticals, and medical devices [2] - Sales grew by over 3% to $20.3 billion in the first six months of the year, despite a 12$3.2 billion in revenue, an 18% increase from the previous year [4] - Recent FDA clearance for two new CGM devices, Libre Rio and Lingo, expands the market beyond insulin-dependent diabetics, potentially accelerating growth [5] - The CGM market is projected to nearly double from $11.6 billion in 2024 to$21.3 billion by 2029, with Abbott Laboratories positioned as a key player [5] Investment Recommendation - Abbott Laboratories is considered a better growth investment compared to Johnson & Johnson due to its lower risk profile and strong growth potential in the medical device sector [6][7]